Cue Biopharma (CUE) CMO Dominique Borie Receives Award

What Happened

• Dominique Christian Borie, Chief Medical Officer & Head of R&D at Cue Biopharma (CUE), was granted equity awards on July 13, 2026. The filing reports two awards: 31,500 restricted stock units (RSUs) and a separate 63,000-share derivative award. Both were recorded as acquired at $0.00 (i.e., granted, not purchased for cash).

Key Details

• Transaction date: July 13, 2026; Form 4 filed July 15, 2026 (appears timely — within the typical 2-business-day window).
• Awards: 31,500 RSUs (grant) and 63,000-share derivative award; both reported with $0 purchase price.
• Vesting/exercisability: RSUs vest in equal quarterly installments over four years from July 13, 2026 (F1). The derivative award (stock option) becomes exercisable in equal quarterly installments over four years from July 13, 2026 (F2).
• Shares owned after the transaction: not disclosed in the filing.
• No indications of tax withholding, 10b5-1 plan, or sale/cashless exercise in this filing.

Context

• These are grant awards, not open-market purchases or sales, so they represent compensation/retention incentives rather than an immediate insider buy or sell signal. The grants have multi-year vesting/exercise schedules, meaning the shares will only become available over time if Borie remains with the company.